Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Barr Laboratory BRL -- Ignore unavailable to you. Want to Upgrade?

To: James Silverman who wrote (88)	11/3/1997 5:55:00 AM
From: harkenman	Respond to of 207

I agree with you. BRL may not give the wiggles that a lot of short trader is looking for. On the long run BRL has averaged about a 100% on a yearly basis if you get in at the right price.

To: James Silverman who wrote (88)	1/22/1998 9:19:00 PM
From: harkenman	Read Replies (1) \| Respond to of 207

Barr Labs 2Q Net 27c A Share On 4c Charge Vs 10c Earnings almost tripled! Dow Jones Newswires Barr Labs - Pomona, N.Y. 2nd Quar Dec. 31: 1997 1996 Revenues $92,328,000 $67,335,000 Net income a 6,325,000 2,228,000 Shr earns (diluted*) Net income a .27 .10 6 Months: Revenues 188,595,000 131,566,000 Net income a 16,722,000 3,995,000 Shr earns (diluted) Net income a .72 .18 a. Includes loss of 4 cents a share from early extinguishment of debt. Excluding loss, net income was 31 cents a share for the quarter and 76 cents a share for the six-month period. - 'Basic' earnings per share is calculated by dividing net earnings applicable to common shares by common shares outstanding. This replaces 'primary' earnings per share, which include common stock equivalents in the calculation. The year ago per share amounts are restated to reflect the current presentation. Barr Labs Inc. (BRL) develops generic drugs to treat illnesses such as cancer, heart disease, depression and hypertension.